Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence.

Giovannoni G, Southam E, Waubant E.

Mult Scler. 2012 Jul;18(7):932-46. doi: 10.1177/1352458511433302. Epub 2012 Jan 16. Review.

PMID:
22249762
2.

Fos expression in the brains of rats performing an attentional set-shifting task.

Burnham KE, Bannerman DM, Dawson LA, Southam E, Sharp T, Baxter MG.

Neuroscience. 2010 Dec 1;171(2):485-95. doi: 10.1016/j.neuroscience.2010.09.008. Epub 2010 Sep 16.

3.

Activation of 5-HT(6) receptors facilitates attentional set shifting.

Burnham KE, Baxter MG, Bainton JR, Southam E, Dawson LA, Bannerman DM, Sharp T.

Psychopharmacology (Berl). 2010 Jan;208(1):13-21. doi: 10.1007/s00213-009-1701-6. Epub 2009 Nov 10.

PMID:
19902184
4.

In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.

Dawson LA, Langmead CJ, Dada A, Watson JM, Wu Z, de la Flor R, Jones GA, Cluderay JE, Southam E, Murkitt GS, Hill MD, Jones DN, Davies CH, Hagan JJ, Smith PW.

Eur J Pharmacol. 2010 Feb 10;627(1-3):106-14. doi: 10.1016/j.ejphar.2009.10.054. Epub 2009 Oct 30.

PMID:
19879867
5.

Increased expression of the NR2A NMDA receptor subunit in the prefrontal cortex of rats reared in isolation.

Turnock-Jones JJ, Jennings CA, Robbins MJ, Cluderay JE, Cilia J, Reid JL, Taylor A, Jones DN, Emson PC, Southam E.

Synapse. 2009 Oct;63(10):836-46. doi: 10.1002/syn.20665.

PMID:
19533626
6.

Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat.

Woolley ML, Waters KA, Gartlon JE, Lacroix LP, Jennings C, Shaughnessy F, Ong A, Pemberton DJ, Harries MH, Southam E, Jones DN, Dawson LA.

Psychopharmacology (Berl). 2009 Jan;202(1-3):343-54. doi: 10.1007/s00213-008-1325-2. Epub 2008 Sep 16.

PMID:
18795266
7.

Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040.

Southam E, Cilia J, Gartlon JE, Woolley ML, Lacroix LP, Jennings CA, Cluderay JE, Reavill C, Rourke C, Wilson DM, Dawson LA, Medhurst AD, Jones DN.

Psychopharmacology (Berl). 2009 Jan;201(4):483-94. doi: 10.1007/s00213-008-1310-9. Epub 2008 Sep 3.

PMID:
18762914
8.

Chandelier cartridges in the prefrontal cortex are reduced in isolation reared rats.

Bloomfield C, French SJ, Jones DN, Reavill C, Southam E, Cilia J, Totterdell S.

Synapse. 2008 Aug;62(8):628-31. doi: 10.1002/syn.20521.

PMID:
18512213
9.

In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia.

Dawson LA, Cato KJ, Scott C, Watson JM, Wood MD, Foxton R, de la Flor R, Jones GA, Kew JN, Cluderay JE, Southam E, Murkitt GS, Gartlon J, Pemberton DJ, Jones DN, Davies CH, Hagan J.

Neuropsychopharmacology. 2008 Jun;33(7):1642-52. Epub 2007 Aug 29.

10.

Effect of the selective dopamine D3 receptor antagonist SB-277011-A on regional c-Fos-like expression in rat forebrain.

Southam E, Lloyd A, Jennings CA, Cluderay JE, Cilia J, Gartlon JE, Jones DN.

Brain Res. 2007 May 29;1149:50-7. Epub 2007 Feb 28.

PMID:
17382304
11.

GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.

Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, Cilia J, Cluderay JE, Crook B, Davis JB, Davis RK, Davis RP, Dawson LA, Foley AG, Gartlon J, Gonzalez MI, Heslop T, Hirst WD, Jennings C, Jones DN, Lacroix LP, Martyn A, Ociepka S, Ray A, Regan CM, Roberts JC, Schogger J, Southam E, Stean TO, Trail BK, Upton N, Wadsworth G, Wald JA, White T, Witherington J, Woolley ML, Worby A, Wilson DM.

J Pharmacol Exp Ther. 2007 Jun;321(3):1032-45. Epub 2007 Feb 27.

PMID:
17327487
12.

Medial prefrontal cortex volume loss in rats with isolation rearing-induced deficits in prepulse inhibition of acoustic startle.

Day-Wilson KM, Jones DN, Southam E, Cilia J, Totterdell S.

Neuroscience. 2006 Sep 1;141(3):1113-21. Epub 2006 Jun 5.

PMID:
16750891
13.

Anticonvulsant mechanisms for today and tomorrow.

Southam E, Stratton SC, Davies CH.

Drug News Perspect. 2005 Oct;18(8):483-7.

PMID:
16391717
14.

The effects of ziprasidone on regional c-Fos expression in the rat forebrain.

Jennings CA, Cluderay JE, Gartlon J, Cilia J, Lloyd A, Jones DN, Southam E.

Psychopharmacology (Berl). 2006 Jan;184(1):13-20. Epub 2005 Dec 3.

PMID:
16328378
15.

Effect of lamotrigine on the activities of monoamine oxidases A and B in vitro and on monoamine disposition in vivo.

Southam E, Pereira R, Stratton SC, Sargent R, Ford AJ, Butterfield LJ, Wheable JD, Beckett SR, Roe C, Marsden CA, Hagan RM.

Eur J Pharmacol. 2005 Sep 20;519(3):237-45.

PMID:
16129425
16.

Reversal of isolation-rearing-induced PPI deficits by an alpha7 nicotinic receptor agonist.

Cilia J, Cluderay JE, Robbins MJ, Reavill C, Southam E, Kew JN, Jones DN.

Psychopharmacology (Berl). 2005 Oct;182(2):214-9. Epub 2005 Oct 19.

PMID:
16001118
17.

A comparison of possible markers for chandelier cartridges in rat medial prefrontal cortex and hippocampus.

Hardwick C, French SJ, Southam E, Totterdell S.

Brain Res. 2005 Jan 21;1031(2):238-44.

PMID:
15649449
18.

Broad spectrum anticonvulsant activity of BW534U87: possible role of an adenosine-dependent mechanism.

Southam E, Stratton SC, Sargent RS, Brackenborough KT, Duffy C, Hagan RM, Pratt GD, Jones SA, Morgan PF.

Pharmacol Biochem Behav. 2002 Dec;74(1):111-8.

PMID:
12376158
19.

Measurement of cGMP and soluble guanylyl cyclase activity.

Southam E.

Curr Protoc Toxicol. 2001 May;Chapter 10:Unit 10.5. doi: 10.1002/0471140856.tx1005s04.

PMID:
23045027
20.

Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats.

Southam E, Kirkby D, Higgins GA, Hagan RM.

Eur J Pharmacol. 1998 Sep 25;358(1):19-24.

PMID:
9809864
21.

The nitric oxide-cyclic GMP pathway and synaptic plasticity in the rat superior cervical ganglion.

Southam E, Charles SL, Garthwaite J.

Br J Pharmacol. 1996 Oct;119(3):527-32.

22.

Nitric oxide-cyclic GMP pathway in brain slices.

Southam E, Garthwaite J.

Methods Enzymol. 1996;269:129-33. Review. No abstract available.

PMID:
8791643
23.

Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase.

Boulton CL, Southam E, Garthwaite J.

Neuroscience. 1995 Dec;69(3):699-703.

PMID:
8596640
24.

Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.

Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B.

Mol Pharmacol. 1995 Aug;48(2):184-8.

PMID:
7544433
25.

The nitric oxide--cyclic GMP pathway and synaptic depression in rat hippocampal slices.

Boulton CL, Irving AJ, Southam E, Potier B, Garthwaite J, Collingridge GL.

Eur J Neurosci. 1994 Oct 1;6(10):1528-35.

PMID:
7850017
26.

The NO-cGMP pathway in neonatal rat dorsal horn.

Morris R, Southam E, Gittins SR, de Vente J, Garthwaite J.

Eur J Neurosci. 1994 May 1;6(5):876-9.

PMID:
7521251
27.

The nitric oxide-cyclic GMP signalling pathway in rat brain.

Southam E, Garthwaite J.

Neuropharmacology. 1993 Nov;32(11):1267-77.

PMID:
7509051
28.
29.

NADPH-diaphorase staining in autonomic and somatic cranial ganglia of the rat.

Morris R, Southam E, Gittins SR, Garthwaite J.

Neuroreport. 1993 Jan;4(1):62-4.

PMID:
8453037
30.

Sources and targets of nitric oxide in rat cerebellum.

Southam E, Morris R, Garthwaite J.

Neurosci Lett. 1992 Mar 30;137(2):241-4.

PMID:
1316590
31.

Nitric oxide may act as a messenger between dorsal root ganglion neurones and their satellite cells.

Morris R, Southam E, Braid DJ, Garthwaite J.

Neurosci Lett. 1992 Mar 16;137(1):29-32.

PMID:
1378218
32.

Intercellular action of nitric oxide in adult rat cerebellar slices.

Southam E, Garthwaite J.

Neuroreport. 1991 Nov;2(11):658-60.

PMID:
1687356
33.

Comparative effects of some nitric oxide donors on cyclic GMP levels in rat cerebellar slices.

Southam E, Garthwaite J.

Neurosci Lett. 1991 Sep 2;130(1):107-11.

PMID:
1660968
34.
35.

Experimental vitamin E deficiency in rats. Morphological and functional evidence of abnormal axonal transport secondary to free radical damage.

Southam E, Thomas PK, King RH, Goss-Sampson MA, Muller DP.

Brain. 1991 Apr;114 ( Pt 2):915-36.

PMID:
1710528
36.

Climbing Fibres as a Source of Nitric Oxide in the Cerebellum.

Southam E, Garthwaite J.

Eur J Neurosci. 1991;3(4):379-382.

PMID:
12106196
37.

A kainate receptor linked to nitric oxide synthesis from arginine.

Garthwaite J, Southam E, Anderton M.

J Neurochem. 1989 Dec;53(6):1952-4.

PMID:
2553870
38.

Vitamin E deficiency and its clinical significance in adults with primary biliary cirrhosis and other forms of chronic liver disease.

Jeffrey GP, Muller DP, Burroughs AK, Matthews S, Kemp C, Epstein O, Metcalfe TA, Southam E, Tazir-Melboucy M, Thomas PK, et al.

J Hepatol. 1987 Jun;4(3):307-17.

PMID:
3036938
39.

Influence of carcass weight upon carcass composition and consumer preference for lamb.

Southam ER, Field RA.

J Anim Sci. 1969 May;28(5):584-8. No abstract available.

PMID:
5391002

Supplemental Content

Loading ...
Support Center